KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVA) EPS (Basic) (2016 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed EPS (Basic) for 10 consecutive years, with $0.42 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Basic) rose 321.05% year-over-year to $0.42, compared with a TTM value of $0.03 through Dec 2025, up 102.07%, and an annual FY2025 reading of $1.23, up 184.83% over the prior year.
  • EPS (Basic) was $0.42 for Q4 2025 at Teva Pharmaceutical Industries, down from $0.56 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $0.56 in Q3 2025 and bottomed at -$1.17 in Q4 2022.
  • Average EPS (Basic) over 5 years is -$0.12, with a median of -$0.04 recorded in 2024.
  • The sharpest move saw EPS (Basic) tumbled 1328.57% in 2022, then surged 321.05% in 2025.
  • Year by year, EPS (Basic) stood at -$0.14 in 2021, then crashed by 735.71% to -$1.17 in 2022, then skyrocketed by 132.48% to $0.38 in 2023, then crashed by 150.0% to -$0.19 in 2024, then soared by 321.05% to $0.42 in 2025.
  • Business Quant data shows EPS (Basic) for TEVA at $0.42 in Q4 2025, $0.56 in Q3 2025, and $0.18 in Q2 2025.